Title |
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, June 2016
|
DOI | 10.1186/s40425-016-0140-2 |
Pubmed ID | |
Authors |
Jason J. Luke, Yuanyuan Zha, Karen Matijevich, Thomas F. Gajewski |
Abstract |
Depletion of CD25(+) Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25(+) T cells. Prior clinical trials of denileukin diftitox suggested reduction of FoxP3(+) Tregs and some clinical responses. To investigate the immunologic effects of denileukin difitox on vaccine-specific immune responses in melanoma, a randomized clinical trial of single dose denileukin diftitox prior to vaccination versus vaccination alone in subjects with HLA-A2(+) metastatic melanoma was performed. Treatment included randomization to a 4-peptide vaccine (Melan-A, gp100, MAGE3 and NA17 with GM-CSF emulsified in Montanide) alone or after single dose of denileukin diftitox (18 mcg/kg). Vaccine was given every 2 weeks for 3 doses and, absent clinical progression, continued every 2 weeks. Blood and tumor biopsies were obtained pretreatment and after 3 vaccinations for immunologic assessments. In 17 treated subjects there were no drug-related G3-4 adverse events. One partial response and 8 stable disease were observed in 9 subjects (4 DD: 5 vaccine only) with no impact of denileukin diftitox on time to progression. Total peripheral Tregs were not significantly altered, and in 1 patient biopsy intra-tumoral FoxP3 transcripts were not reduced following denileukin diftitox. ELISA for IL2R-α demonstrated no impact on outcomes by soluble CD25 level. Immune monitoring suggested the development of modest vaccine-specific CD8(+) T cell responses in the control group, however immunization efficacy was actually reduced in the denileukin diftitox group. Our results indicate that denileukin diftitox did not effectively deplete Tregs, augment T cell responses, or improve clinical activity in melanoma. Clinicaltrials.gov ID: NCT00515528; Registered August 9, 2007. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 3% |
Unknown | 34 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 17% |
Other | 4 | 11% |
Student > Master | 4 | 11% |
Student > Ph. D. Student | 3 | 9% |
Student > Bachelor | 2 | 6% |
Other | 4 | 11% |
Unknown | 12 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 26% |
Immunology and Microbiology | 5 | 14% |
Agricultural and Biological Sciences | 2 | 6% |
Nursing and Health Professions | 1 | 3% |
Computer Science | 1 | 3% |
Other | 5 | 14% |
Unknown | 12 | 34% |